이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

Copanlisib in Association With Cetuximab in Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinomas Harboring a PI3KCA Mutation/Amplification and/or a PTEN Loss (COPAN-ORL06)

2021년 3월 24일 업데이트: UNICANCER

Phase ib/II Trial of Copanlisib, a Selective PI3K Inhibitor, in Combination With Cetuximab in Patients With Recurrent and/or Metastatic (R/M) Head and Neck Squamous Cell Carcinoma (HNSCC) Harboring a PI3KCA Mutation/Amplification and/or a PTEN Loss.

The study consists of two distinct and sequential parts:

  • A Phase Ib aimed at determining the MTD (Maximum Tolerated Dose) of the combination (copanlisib/cetuximab) and the RP2D
  • A Phase II aimed at evaluating the efficacy of the combination at the RP2D (Recommended Phase 2 Dose)

All patients will be treated with the Copanlisib, a selective PI3KCA inhibitor, in association with Cetuximab.

연구 개요

상태

종료됨

정황

개입 / 치료

연구 유형

중재적

등록 (실제)

11

단계

  • 2 단계
  • 1단계

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 장소

      • Angers, 프랑스, 49933
        • Institut de Cancérologie de l'Ouest
      • Dijon, 프랑스, 21079
        • Centre Georges François Leclerc
      • Lille, 프랑스, 59020
        • Centre Oscar Lambret
      • Lyon, 프랑스, 69437
        • Centre Léon Bérard
      • Nancy, 프랑스, 54511
        • Institut de Cancérologie de Lorraine
      • Nice, 프랑스, 06189
        • Centre Antoine Lacassagne
      • Paris, 프랑스, 75005
        • Institut Curie

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

18년 이상 (성인, 고령자)

건강한 자원 봉사자를 받아들입니다

아니

연구 대상 성별

모두

설명

Inclusion Criteria:

  1. Patients with R/M HNSCC (oropharynx, oral cavity, hypopharynx and larynx), histologically or cytologically confirmed, not amenable to curative treatment with surgery and/or chemotherapy and/or radiotherapy (Stage III/IV)
  2. Adult men and women ≥ 18 years
  3. Patients with Eastern Cooperative Oncology Group (ECOG) performance status 0 - 2
  4. Patients with tumor harboring a PI3K mutation/amplification and/or a PTEN loss
  5. Patients with a radiologic documented progression or relapse after cetuximab therapy (patients could have either received combination platinum doublet with cetuximab or cetuximab after platinum doublet)
  6. Patients with prior platinum based therapy, unless contraindicated
  7. Patients with at least one measurable lesion assessed by Magnetic Resonance Imaging (MRI) or a computerized tomography scanner (CT-scan) according to RECIST v1.1. Patients must have clinically and/or radiographically documented measurable disease. At least one site of disease must be unidimensionally measurable as follows

    • CT-scan, physical exam ≥ 10 mm
    • Lymph node short axis ≥ 15 mm Tumor measurements must be performed within 28 days prior to starting study drug
  8. Women of childbearing potential and men must agree to use adequate contraception when sexually active. This applies since signing of the informed consent form and up to 12 months (for women of child bearing potential) and 6 months (for fertile men) after the last study drug administration (Copanlisib). Highly effective contraception methods are detailed in section 7.2
  9. Women of childbearing age or sexually active female patients with reproductive potential must have a negative pregnancy test (serum or urine within the 7 days prior to starting study drug)
  10. Provision of signed and dated, written informed consent prior to any study specific procedures, sampling and analyses
  11. Patients with social insurance coverage
  12. Glomerular filtration rate (GFR) ≥ 40 mL/min/1.73 m² according to the Modification of Diet in Renal Disease (MDRD) abbreviated formula (within 7 days prior to starting study drug). If not on target, this evaluation may be repeated once after at least 24 hours either according to the MDRD abbreviated formula or by 24 hour sampling. If the later result is within acceptable range, it may be used to fulfill the inclusion criteria instead

Exclusion Criteria:

  1. Patients previously treated with PI3K and/or mTOR inhibitors
  2. Patients with anticancer therapy (radiotherapy, immunotherapy, chemotherapy, etc.) within 28 days or investigational treatment within 28 days prior to the initiation of study drug treatment, unless evidence of progression since last treatment
  3. Patients currently using other approved or investigational anti-neoplasic agent
  4. Patients with uncontrolled arterial hypertension despite optimal medical management, Congestive heart failure > New York Heart Association (NYHA) class 2, Unstable angina (angina symptoms at rest), new-onset angina (begun within the last 3 months). Myocardial infarction less than 6 months before start of test drug No active cardiac disease including any of the following: left ventricular ejection fraction (LVEF) < 50% as determined by Multiple Gated Acquisition (MUGA) scan or echocardiogram (ECHO) and QTc > 470 ms on screening ECG
  5. Patients with uncontrolled diabetes mellitus (patients with controlled Type I or II diabetes mellitus will be eligible but only into the phase II of the study and only if fasting HbA1c ≤ 8.5% at screening)
  6. Patients with a history of Human Immunodeficiency Virus (HIV) Hepatitis B (HBV) or hepatitis C (HCV) infection. All patients must be screened for HIV, HBV and HCV up to 28 days prior to first dosing using the routine virus laboratorial panel. Patients who are positive for HBs Ag or HBc Ab will be eligible if they are negative for HBV-DNA. Patients who are positive for anti-HCV antibody will be eligible if they are negative for HCV-RNA
  7. Patients with active uncontrolled or symptomatic central nervous system (CNS) metastases. Patients are eligible if their disease is controlled at least 30 days on corticosteroids prior to starting study drug
  8. Patients with major surgery within 28 days, or open biopsy within 7 days, prior to starting study drug. Patients must have recovered from major side effects of the surgery
  9. Patients receiving any medications or substances that are inhibitors or inducers of CYP3A4 are ineligible. Copanlisib is primarily metabolized by CYP3A4. Therefore concomitant use of strong inhibitors of CyP3A4 (e.g., ketoconazole, itraconazole, clarithromycin, ritonavir, indinavir, nelfinavir and saquinavir), and inducers of CYP3A (e.g. rifampin, phenytoin, carbamazepine, phenobarbital, st. John's Wort) are not permitted from Day -14 of Cycle 1 until the Safety follow up visit
  10. Patients with altered hematopoietic or organ function, as indicated by the following criteria (assessed within 7 days prior the first dosing):

    • Absolute granulocytes < 1.0 x 10⁹/L
    • Platelets < 75 x 10⁹/L
    • ALAT/ASAT > 2.5 x ULN in the absence of or > 5 x ULN in the presence of liver metastases
    • Bilirubin > 1.5 x ULN (except Gilbert Syndrome: < 3.0 mg/dL)
    • Creatinine clearance < 60 mL/min (measured or calculated by Cockcroft and Gault formula) or serum creatinine > 1.0 x ULN
    • Lipase > 1.5 x ULN
    • INR and PTT > 1.5 x ULN
  11. Patients with a history of hypersensitivity to other monoclonal antibodies or to the active or inactive excipients of study drug
  12. Known drug or alcohol abuse
  13. Known or underlying medical condition that, in the investigator's opinion, would make the administration of study drug hazardous to the patient or obscure the interpretation of toxicity determination or adverse events
  14. History of uncontrolled seizures, seizure disorder requiring medication, central nervous system disorders or psychiatric disability judged by the investigator to be clinically significant, precluding informed consent, or interfering with compliance of oral drug intake
  15. Unwillingness to give written informed consent, unwillingness to participate, or inability to comply with the protocol for the duration of the study
  16. Individuals deprived of liberty or placed under the authority of a tutor
  17. Previous or concurrent history of malignancies within 5 years prior to study treatment except for curatively treated:

    • Cervical carcinoma in situ
    • Non-melanoma skin cancer
    • Superficial bladder cancer (Ta [non-invasive tumor], Tis [carcinoma in situ] and T1 [tumor invades lamina propria])
    • Localized prostate cancer
  18. Patients with evidence or history of bleeding diathesis. Any hemorrhage or bleeding event ≥ CTCAE Grade 3 within 4 weeks prior to the start of study medication
  19. Proteinuria of ≥ CTCAE Grade 3 as assessed by a 24h protein quantification or estimated by urine protein-creatinine ratio > 3.5 on a random urine sample
  20. History or concurrent condition of interstitial lung disease of any severity and/or severely impaired lung function (as judged by the investigator)
  21. Concurrent diagnosis of pheochromocytoma
  22. Pregnant or breast-feeding patients. Women of childbearing potential must have a serum pregnancy test performed a maximum of 7 days before start of treatment, and a negative result must be documented before start of treatment
  23. Unresolved toxicity higher than CTCAE Grade 1 attributed to any prior therapy/procedure, excluding alopecia
  24. Ongoing immunosuppressive therapy
  25. Blood or platelets transfusion less than 7 days before starting treatment
  26. Myeloid growth factors within 14 days prior to treatment
  27. Systemic continuous corticosteroid therapy at a daily dose higher than 15 mg prednisone or equivalent is not allowed. Previous corticosteroid therapy must be stopped or reduced to the allowed dose 7 days before performing the screening CT scan/MRI, whichever is performed first, and again prior to the first study drug administration. If a patient is on chronic corticosteroid therapy, corticosteroids should be de-escalated to the maximum allowed dose after the patient has signed the IC. Patients may be using topical or inhaled corticosteroids
  28. History of having received an allogeneic bone marrow or organ transplant
  29. Anti-arrhythmic therapy (beta blockers or digoxin are permitted)

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 주 목적: 치료
  • 할당: 해당 없음
  • 중재 모델: 단일 그룹 할당
  • 마스킹: 없음(오픈 라벨)

무기와 개입

참가자 그룹 / 팔
개입 / 치료
실험적: Copanlisib + Cetuximab
All patients will be treated by Copanlisib in association with Cetuximab.
Copanlisib will be given at Day 1, Day 8 and Day 15 (1 cycle = 28 days), administered intravenously over 60 minutes, in association with Cetuximab.
다른 이름들:
  • 베이 80-6946
Cetuximab will be given weekly at Day 1, Day 8, Day 15 and Day 22 (1 cycle = 28 days), administered intravenously over 120 minutes (Cycle 1 Day 1) or 60 minutes (subsequent infusions), in association with Copanlisib.
다른 이름들:
  • 얼비툭스

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
Phase Ib (dose escalation phase): to determine the Maximal Tolerated Dose (MTD) and the Recommended Phase 2 Dose (RP2D) of Copanlisib in association with Cetuximab
기간: 1 month
Determination of the MTD will be based on the occurence of Dose Limiting Toxicities during Cycle 1.
1 month
Phase II (expansion phase) : to assess the efficacy of the combination (Copanlisib + Cetuximab) at the RP2D.
기간: 16 weeks
Efficacy of the combination will be assessed through Progression Free Survival at week 16.
16 weeks

2차 결과 측정

결과 측정
측정값 설명
기간
Efficacy of the combination
기간: Through the study completion with an average of 10 months
Objective Response Rate (ORR) using RECIST 1.1 criteria
Through the study completion with an average of 10 months
Efficacy of the combination
기간: Through the study completion with an average of 10 months
Overall Survival (OS)
Through the study completion with an average of 10 months
Adverse Events (NCI CTCAE v4.0)
기간: Up to 15 cycles
All Adverse Events (NCI CTCAE v4.0), related or not related to Copanlisib or Cetuximab, will be collected in the Case Report Form in order to picture the safety profile of the association.
Up to 15 cycles
Copanlisib Maximum Plasma Concentration [Cmax]
기간: First Month (at Day 1 and Day 15)
For patients enrolled in the phase Ib (dose escalation phase) pharmacokinetic samples (blood) will be collected at Cycle 1 Day 1 and Cycle 1 Day 15. There will be 5 samples per day: pre-infusion, end of infusion, 2 hours, 8 hours and 24 hours after the start of Copanlisib infusion.
First Month (at Day 1 and Day 15)
Area Under the Curve [AUC] for Copanlisib pharmacokinetic
기간: First Month (at Day 1 and Day 15)
For patients enrolled in the phase Ib (dose escalation phase) pharmacokinetic samples (blood) will be collected at Cycle 1 Day 1 and Cycle 1 Day 15. There will be 5 samples per day: pre-infusion, end of infusion, 2 hours, 8 hours and 24 hours after the start of Copanlisib infusion.
First Month (at Day 1 and Day 15)
Mutational profile of circulating tumoral DNA (ctDNA)
기간: through the study duration: baseline, C1D1, C1D15, 8 weeks, disease progression
For patients enrolled in the phase II (dose escalation phase) blood samples will be collected at baseline, C1D1, C1D15, 8 weeks, Disease progression or end of treatment whichever comes first.
through the study duration: baseline, C1D1, C1D15, 8 weeks, disease progression

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

스폰서

간행물 및 유용한 링크

연구에 대한 정보 입력을 담당하는 사람이 자발적으로 이러한 간행물을 제공합니다. 이것은 연구와 관련된 모든 것에 관한 것일 수 있습니다.

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (실제)

2016년 6월 1일

기본 완료 (실제)

2019년 10월 9일

연구 완료 (실제)

2019년 10월 9일

연구 등록 날짜

최초 제출

2016년 6월 16일

QC 기준을 충족하는 최초 제출

2016년 6월 29일

처음 게시됨 (추정)

2016년 7월 4일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2021년 3월 29일

QC 기준을 충족하는 마지막 업데이트 제출

2021년 3월 24일

마지막으로 확인됨

2021년 3월 1일

추가 정보

이 연구와 관련된 용어

기타 연구 ID 번호

  • UC-0130/1507
  • 2015-004340-19 (EudraCT 번호)

개별 참가자 데이터(IPD) 계획

개별 참가자 데이터(IPD)를 공유할 계획입니까?

아니

IPD 계획 설명

Individual Participant Data will not be shared at an individual level. Those data will be part of the study database including all enrolled patients.

약물 및 장치 정보, 연구 문서

미국 FDA 규제 의약품 연구

아니

미국 FDA 규제 기기 제품 연구

아니

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .